Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance)

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|120|22|3575-3583

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.22, 2014-11, pp. : 3575-3583

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Palonosetron for chemotherapy-induced nausea and vomiting

By  

Inpharma, Vol. 1, Iss. 1412, 2003-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Gabapentin Extended-Release Tablets for the Treatment of Patients with Postherpetic Neuralgia: A Randomized, Double-Blind, Placebo-Controlled, Multicentre Study

By Wallace Mark S.  

Clinical Drug Investigation, Vol. 30, Iss. 11, 2010-11 ,pp. : 765-776

Adis International

Access to resources Recommend Favorite

Risk–benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting

By Herrstedt Jørn  

Expert Opinion on Drug Safety, Vol. 3, Iss. 3, 2004-05 ,pp. : 231-248

Informa Healthcare

Access to resources Recommend Favorite

Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting

By Ruhlmann Christina H   Herrstedt Jøørn  

Expert Opinion on Drug Safety, Vol. 10, Iss. 3, 2011-05 ,pp. : 449-462

Informa Healthcare

Access to resources Recommend Favorite

Aprepitant: A Review of its Use in the Prevention of Chemotherapy-Induced Nausea and Vomiting

By Dando T.M.   Perry C.M.  

Drugs, Vol. 64, Iss. 7, 2004-01 ,pp. : 777-794

Adis International

Access to resources Recommend Favorite